Bupropion/zonisamide

From Wikipedia, the free encyclopedia
(Redirected from Empatic)

Template:Short description Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Bupropion/zonisamide
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Combination of
BupropionNorepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
ZonisamideSulfonamide anticonvulsant
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
  • Investigational
Identifiers
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content.  (verify)

Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity.[1][2][3] Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor.[1] The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.[1][4][5]

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b c Page Module:Citation/CS1/styles.css has no content."Bupropion/Zonisamide - AdisInsight".
  2. ^ Page Module:Citation/CS1/styles.css has no content."Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half". Archived from the original on 2010-01-11. Retrieved 2010-01-07.
  3. ^ Page Module:Citation/CS1/styles.css has no content."Empatic Obesity Drug Information and News". Archived from the original on 2017-07-02. Retrieved 2010-01-07.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Ioannides-Demos LL, Piccenna L, McNeil JJ (2011). "Pharmacotherapies for obesity: past, current, and future therapies" (PDF). Journal of Obesity. 2011 179674. doi:10.1155/2011/179674. PMC 3006492. PMID 21197148.
  5. ^ Page Module:Citation/CS1/styles.css has no content.Adan RA (February 2013). "Mechanisms underlying current and future anti-obesity drugs". Trends in Neurosciences. 36 (2): 133–40. doi:10.1016/j.tins.2012.12.001. PMID 23312373. S2CID 21974224.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Monoamine reuptake inhibitors Template:Nicotinic acetylcholine receptor modulators


Template:Asbox

Retrieved from "https://cosmopedia.co/index.php?title=Bupropion/zonisamide&oldid=8141638"